08/31/23 8:30 AMNasdaq : HALO conferencesHalozyme to Present at Upcoming Investor ConferencesHalozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow:.RHEA-AIneutral
08/08/23 4:01 PMNasdaq : HALO earningsHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTSRevenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1. Royalty Revenue Increased 31% YOY to Record $111.7 million. "Our strong second quarter results with record revenue of $221 million and non-GAAP EPS of $0.74 were complemented with significant commercial and clinical advancements with our ENHANZE...RHEA-AIneutral
07/25/23 8:30 AMNasdaq : HALO conferencesearningsHalozyme To Report Second Quarter 2023 Financial and Operating ResultsHalozyme Therapeutics, Inc. today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading. Halozyme will host a conference call on Tuesday, August 8, 2023 at 4:30 p.m. ET/1: 30 p.m. PT to discuss the results.RHEA-AIneutral
07/17/23 1:15 AMNasdaq : HALO Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating PolyneuropathyHalozyme Therapeutics, Inc. today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART ® Hytrulo with ENHANZE ® in adults with chronic inflammatory demyelinating polyneuropathy. The study met its primary endpoint demonstrating a significantly lower risk of relapse with...RHEA-AIneutral
07/13/23 1:15 AMNasdaq : HALO clinical trialPositive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple SclerosisHalozyme Therapeutics, Inc. today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS ® with ENHANZE ® as a twice a year 10- minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis or primary progressive MS. OCREVUS subcutaneous...RHEA-AIneutral
06/20/23 6:30 PMNasdaq : HALO fda approvalHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia GravisHalozyme Therapeutics, Inc. today announced that argenx received U.S. Food and Drug Administration approval for VYVGART ® Hytrulo injection with ENHANZE ® for subcutaneous use for the treatment of generalized...RHEA-AIneutral
06/06/23 8:30 AMNasdaq : HALO conferencesHalozyme to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceHalozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8 a.m. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the...RHEA-AIneutral
05/09/23 4:01 PMNasdaq : HALO earningsHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTSRevenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1. Royalty Revenue Increased 43% YOY to $99.6 million. Reiterating 2023 Revenue Guidance of $815-$845 million, Representing 23-28% YOY Growth; EBITDA of $415-$440 million, Representing > 30% YOY Growth 1.RHEA-AIneutral
05/03/23 8:30 AMNasdaq : HALO conferencesHalozyme to Present at Upcoming Investor ConferencesHalozyme Therapeutics, Inc. today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow:.RHEA-AIneutral
04/25/23 8:30 AMNasdaq : HALO conferencesHalozyme To Report First Quarter 2023 Financial and Operating ResultsHalozyme will host a conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET/ 1:30 p.m. PT to discuss the results. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. Having touched more than 700,000 patient lives in post-marketing use in five...RHEA-AIneutral